Raid Captures 82 Million Doses of Counterfeit Drugs in Africa - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Raid Captures 82 Million Doses of Counterfeit Drugs in Africa


ePT--the Electronic Newsletter of Pharmaceutical Technology

An operation spanning 16 African countries and conducted by the World Customs Organization (WCO) in partnership with the Institute of Research against Counterfeit Medicines (IRACM) led to the seizure of more than 82 million doses of counterfeit medicines. The drugs seized included antimalarials, antibiotics, cough medicines, contraceptive pills, and fertility treatments, and were valued at around $40 million.

The operation was conducted simultaneously at 16 major seaports on the east and west coasts of Africa between July 11, 2012, and July 20, 2012. Customs officials seized more than 100 million counterfeit products of all categories. Of a total of 110 shipping containers inspected, 84 contained counterfeit or illegal products, with the largest shipments found in Angola, Togo, Cameroon, and Ghana. The majority of the shipments originated from South Asia, East Asia, and the Middle East.

According to a joint press release from IRACM and WCO, customs officers involved were trained by WCO, with the support of IRACM and experts from the pharmaceutical sector, to recognize the technical characteristics of various products that are subject to counterfeiting and to implement new detection methods. According to the release, the organizations expect to extend the operation to other continents in the coming months.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here